SynthesisVeterinary research communications2025
Theileria parva genetics, prevalence and vaccination practices in Zimbabwe and the African region and the prospects for vaccine development: a systematic review.
Synthesis in Veterinary research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionJanuary disease causes the deaths of over 55,000 cattle valued at approximately US$ 17 million annually in Zimbabwe. The locally developed Boleni stabilate vaccine is in use for controlling the disease. In the present review, we show the current knowledge of the genetic variation and population structure of Theileria parva parasite and its implications on the epidemiology and control of the parasite in eastern and southern Africa, with a major emphasis on Zimbabwe.
methodsA systematic review was conducted to analyse the reports available in literature in order to map the Theileria parva genetic diversity profile. A total of 103 studies met the criteria for analysis and were included in the review.
resultsThe reports retrieved in this study show that East Coast fever and Corridor disease have been extensively sequenced to establish the parasite population genetic structure. One report described genetic diversity in January disease, with no sequencing tools included. The live sporozoite stabilate administered as infection without concurrent treatment remains the vaccination approach of choice in January disease. DISCUSSION: The adoption of population genetics led to the determination of genotypes that were employed in the development of the Muguga cocktail vaccine. To date, vaccination against East Coast fever is reported to reduce mortality rate. The Boleni isolate remains in use for vaccination against uncharacterized populations of January disease in spite of increased mortality rates extensively reported from 2015 to date. There is need to adopt comparative genomics in vaccine development for a more effective vaccine.
Indexed as
Identifiers
40106054What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.